8 completed. 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
Follow Cefdinir: new trials by email Literature Review of Cefdinir trials Research Report on Cefdinir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cefdinir Capsules 300 mg, Fasting Cefdinir Capsules 300 mg, OMNICEF® 300 mg - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 32 | 2005-07-01 | 2024-08-20 |
| Cefdinir Capsules 300 mg, Non-fasting Cefdinir Capsules 300 mg, OMNICEF® Capsule 300 mg - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 32 | 2005-07-01 | 2024-08-20 |
| To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria), Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA) - Healthy | Phase 1 | Completed | Sandoz | 40 | 2005-04-01 | 2017-03-29 |
| To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions Cefdinir 300 mg Capsule (Sandoz, Austria), Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA) - Healthy | Phase 1 | Completed | Sandoz | 28 | 2005-04-01 | 2017-03-29 |
| To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 300 mg Capsule Fed Conditions Cefdinir 300 mg Capsule (Sandoz, Austria), Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA) - Healthy | Phase 1 | Completed | Sandoz | 28 | 2005-04-01 | 2017-03-29 |
| To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria), Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA) - Healthy | Phase 1 | Completed | Sandoz | 40 | 2005-04-01 | 2017-03-29 |
| Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting Cefdinir for oral suspension 250 mg/5mL, OMNICEF® for oral suspension 250 mg/5mL - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 32 | 2005-03-01 | 2024-08-20 |
| Cefdinir for Oral Suspension 250 mg/5mL, Fasting Cefdinir for oral suspension 250 mg/5mL, OMNICEF® for oral suspension 250 mg/5mL - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 32 | 2005-02-01 | 2024-08-20 |
Sandoz (4) · Teva Pharmaceuticals USA (4)
United States (4)
Richard Larouche, M.D. (3) · Soran Hong, M.D. (2) · Benoit Girard, M.D. (1) · James D. Carlson, M.D. (1) · James D. Carlson, Pharm. D. (1)